Project description
Single-cell technology helps to define sources of nucleotide de novo synthesis
Nucleotide de novo synthesis (DNS) is essential for cell proliferation, and its disruption is detrimental to rapidly multiplying cancer cells. Anti-nucleotide therapy was one of the first approaches to treat cancer, but DNS can be bypassed by the uptake of extracellular nucleotides or through the recycling pathways, limiting therapy efficacy. The cellular sources of nucleotides in normal tissue and tumours in vivo have not yet been adequately characterised; this is the main goal of the EU-funded MetaCross project, in addition to understanding the adaptations to DNS blockade in cancer. The research will involve an integrative in vivo approach using single-cell technology combined with single-cell omics analysis, advanced bioinformatics and state-of-the-art mouse models.
Fields of science
- natural sciencesbiological sciencesbiochemistrybiomoleculesnucleic acids
- medical and health sciencesclinical medicineoncologylung cancer
- natural sciencesbiological sciencesgeneticsnucleotides
- medical and health sciencesmedical biotechnologycells technologies
- medical and health sciencesbasic medicinephysiologyhomeostasis
Programme(s)
Funding Scheme
MSCA-IF-EF-ST - Standard EF
Coordinator
252 50 Vestec
Czechia
See on map